Search

Author/Creator Chiappetta, S.

1. Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. (September 2015)

Authors:
Ripa, M.; Pogliaghi, M.; Chiappetta, S.; Galli, L.; Pensieroso, S.; Cavarelli, M.; Scarlatti, G.; De Biasi, S.; Cossarizza, A.; De Battista, D.; Malnati, M.; Lazzarin, A.; Nozza, S.; Tambussi, G.
Journal:
Clinical microbiology and infection
Issue:
Volume 21:Number 9(2015:Sep.)
Page Start:
876.e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. (May 2015)

Authors:
Nozza, S.; Galli, L.; Antinori, A.; Chiappetta, S.; Mazzotta, F.; Zaccarelli, M.; Ottou, S.; De Battista, D.; Pogliaghi, M.; Di Pietro, M.; Malnati, M.; Ripa, M.; Bonora, S.; Lazzarin, A.
Journal:
Clinical microbiology and infection
Issue:
Volume 21:Number 5(2015:May)
Page Start:
510.e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗